J. Chang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
J. Chang has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
A. Makris
From the Departments of Medicine and Computing, The Royal Marsden Hospital, Sutton, Surrey, United Kingdom; and the Departments of Medical Oncology and Pathology, University of Texas Health Science Center at San Antonio, San Antonio, TX
1 shared publicationC. K. Osborne
From the Departments of Medicine and Computing, The Royal Marsden Hospital, Sutton, Surrey, United Kingdom; and the Departments of Medical Oncology and Pathology, University of Texas Health Science Center at San Antonio, San Antonio, TX
1 shared publicationD. C. Allred
From the Departments of Medicine and Computing, The Royal Marsden Hospital, Sutton, Surrey, United Kingdom; and the Departments of Medical Oncology and Pathology, University of Texas Health Science Center at San Antonio, San Antonio, TX
1 shared publicationG. M. Clark
From the Departments of Medicine and Computing, The Royal Marsden Hospital, Sutton, Surrey, United Kingdom; and the Departments of Medical Oncology and Pathology, University of Texas Health Science Center at San Antonio, San Antonio, TX
1 shared publicationL. Assersohn
From the Departments of Medicine and Computing, The Royal Marsden Hospital, Sutton, Surrey, United Kingdom; and the Departments of Medical Oncology and Pathology, University of Texas Health Science Center at San Antonio, San Antonio, TX
1 shared publicationM. Dowsett
From the Departments of Medicine and Computing, The Royal Marsden Hospital, Sutton, Surrey, United Kingdom; and the Departments of Medical Oncology and Pathology, University of Texas Health Science Center at San Antonio, San Antonio, TX
1 shared publication
Latest Publications
- 1 October 1999
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 17 (10) , 3058-3063
Biologic Markers as Predictors of Clinical Outcome From Systemic Therapy for Primary Operable Breast Cancer
PURPOSE: To determine whether pretreatment clinical features and molecular markers, together with changes in these factors, can predict treatment response and survival in patients with primary operable breast cancer who receive neoadjuvant therapy. PATIENTS AND METHODS: Mitoxantrone, methotrexate (with or without mitomycin), and tamoxifen chemoendocrine therapy was administered to 158 patients before surgery. Clinical response was assessed after four cycles of treatment. Fine-needle aspiration cytology for estrogen receptor (ER), progesterone receptor (PgR), c-erbB-2, p53, bcl-2, Ki67, S-phase fraction (SPF), and ploidy were performed pretreatment and repeated on day 10 or day 21 after the first cycle of treatment. RESULTS: Good clinical response (GCR, defined as complete response or minimal residual disease) was achieved in 31% of patients (49 of 158). Tumor size, nodal disease, response, ER, PgR, c-erbB-2, p53, bcl-2, Ki67, SPF, and ploidy were analyzed as predictors of survival. By univariate analysis, node-positive disease (P = .05), lack of ER (P < .05) and PgR (P < .05), and failure to attain GCR (P = .008) were associated with a significantly increased risk of relapse. A significantly increased risk of death was associated with node-positive disease (P = .02), lack of ER expression (P = .04), and failure to attain GCR. By multivariate analysis, GCR was an independent predictor for survival (P = .05). ER expression (P = .03), absence of c-erbB-2 (P = .03), and a decrease in Ki67 on day 10 or day 21 of the first cycle (P < .05) significantly predicted for subsequent GCR. CONCLUSION: Molecular markers may be used to predict the likelihood of achieving GCR, which seems to be a valid surrogate marker for survival.
- 1 October 1999
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 17 (10) , 3058-3063
Biologic Markers as Predictors of Clinical Outcome From Systemic Therapy for Primary Operable Breast Cancer
PURPOSE: To determine whether pretreatment clinical features and molecular markers, together with changes in these factors, can predict treatment response and survival in patients with primary operable breast cancer who receive neoadjuvant therapy. PATIENTS AND METHODS: Mitoxantrone, methotrexate (with or without mitomycin), and tamoxifen chemoendocrine therapy was administered to 158 patients before surgery. Clinical response was assessed after four cycles of treatment. Fine-needle aspiration cytology for estrogen receptor (ER), progesterone receptor (PgR), c-erbB-2, p53, bcl-2, Ki67, S-phase fraction (SPF), and ploidy were performed pretreatment and repeated on day 10 or day 21 after the first cycle of treatment. RESULTS: Good clinical response (GCR, defined as complete response or minimal residual disease) was achieved in 31% of patients (49 of 158). Tumor size, nodal disease, response, ER, PgR, c-erbB-2, p53, bcl-2, Ki67, SPF, and ploidy were analyzed as predictors of survival. By univariate analysis, node-positive disease (P = .05), lack of ER (P < .05) and PgR (P < .05), and failure to attain GCR (P = .008) were associated with a significantly increased risk of relapse. A significantly increased risk of death was associated with node-positive disease (P = .02), lack of ER expression (P = .04), and failure to attain GCR. By multivariate analysis, GCR was an independent predictor for survival (P = .05). ER expression (P = .03), absence of c-erbB-2 (P = .03), and a decrease in Ki67 on day 10 or day 21 of the first cycle (P < .05) significantly predicted for subsequent GCR. CONCLUSION: Molecular markers may be used to predict the likelihood of achieving GCR, which seems to be a valid surrogate marker for survival.